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Abstract: Neuropathic pain, comprising a
range of heterogeneous conditions, is often
severe and difficult to manage, and this may
result in a chronic condition that negatively
affects the overall functioning and quality of
life in patients. The pharmacotherapy of neu-
ropathic pain is challenging and for many
patients effective treatment is lacking; there-
fore, evidence-based recommendations are
essential. Currently, there is general agreement
on which drugs are appropriate for the first-line
treatment of neuropathic pain, whereas debate
continues regarding second- and third-line
treatments. First-line drugs for neuropathic pain
include antidepressants (tricyclic antidepres-
sants and serotonin–noradrenaline reuptake
inhibitors) and anticonvulsants acting at cal-
cium channels (pregabalin and gabapentin).
Second- and third-line drugs for neuropathic
pain include topical lidocaine and opioids.
Although efficacious in the treatment of neu-
ropathic pain, opioids are not considered to be a
first choice because of adverse drug reactions
and, more recently, because of concerns about
abuse, diversion, and addiction. A clear
understanding of the mechanism of action of
currently available drugs is an essential step
towards an effective clinical approach that aims
to tailor therapies both to the specific neuro-
pathic disease and to the needs of an individual
patient. This review provides an overview of
current drugs available for the treatment of
neuropathic pain with an emphasis on their
mechanism of action.
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INTRODUCTION
Neuropathic pain comprises a wide range of
heterogeneous conditions caused by lesions or
diseases of the somatosensory system, either at
the peripheral or at the central level. Neuro-
pathic pain is often severe and difficult to
manage, resulting in a chronic condition that
negatively affects the overall functioning and
quality of life in patients and leads to a high
economic burden for the individual and society.
The use of effective therapies to control pain
and its consequences is, therefore, of primary
importance. Many different clinical practice
guidelines have been published in the last
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15 years to help clinicians choose appropriate
drugs for the management of neuropathic pain
[1]. When considering the inherent limitations
that are introduced when large amounts of
homogenous studies are combined [2, 3],
emphasis needs to be placed on guidelines that
incorporate practical recommendations made
on clinically based evidence. The overwhelming
majority of these guidelines are the result of an
evidence-based approach, sometimes accompa-
nied by a consensus statement. There is cur-
rently general agreement on which drugs are
appropriate for first-line treatment of neuro-
pathic pain, whereas the debate regarding sec-
ond- and third-line drugs is still open, especially
concerning weak and strong opioids. Although
efficacious in the treatment of neuropathic
pain, opioids are not considered to be a first
choice because of adverse drug reactions and,
more recently, because of concerns about abuse,
diversion, and addiction [4]. First-line drugs for
neuropathic pain include antidepressants (tri-
cyclic antidepressants [TCA] and serotonin–no-
radrenaline reuptake inhibitors [SNRI]) and
anticonvulsants acting at calcium channels
(pregabalin and gabapentin) [5].
Compliance with Ethics Guidelines
This article is based on previously conducted
studies and does not involve any new studies of
human or animal subjects performed by the
author.
FIRST-LINE DRUGS
FOR NEUROPATHIC PAIN
Antidepressants
Antidepressants are among the oldest drugs
used for the treatment of neuropathic pain and
have been the subject of many randomized
controlled trials. They originally came to be
used in the treatment of chronic pain, and in
particular neuropathic pain, because some of
the patients suffering from chronic pain are also
depressed, and these drugs relieve pain as well
as depression. However, an independent
analgesic action has been reported for TCAs
since the 1960s. Pain relief has since been
described in depressed and non-depressed
patients with chronic pain. The relief can be
more rapid in some patients and appears to
occur at a lower dose than the antidepressant
effect [6]. An early concept of the mechanism of
antidepressant analgesia was that these drugs
are capable of potentiating the activity of the
descending inhibitory pathways extending
from the brain stem to the dorsal horn of the
spinal cord, mainly by inhibiting the reuptake
of serotonin and noradrenaline that descending
fibers release into the spinal synapses between
nociceptors (or first-order neurons) and the
spinothalamic neurons (or second-order neu-
rons). At this level, neurotransmitters can inhi-
bit synaptic transmission between first- and
second-order neurons directly, by binding to
membrane receptors expressed on the surface of
these neurons, as in the case of noradrenaline
that binds alpha-2 adrenergic receptors. Alter-
natively, they can activate interneurons that in
turn release inhibitory substances such as
endogenous opioids or gamma-aminobutyric
acid (GABA), as in the case of serotonin at its
metabotropic receptors or noradrenaline at
alpha-1 adrenergic receptors [7]. Recently, some
studies highlighted a possible peripheral mech-
anism for the action of antidepressants. Bohren
and colleagues examined the effect of nora-
drenergic lesions at different levels of the ner-
vous system and concluded that the analgesic
properties of long-term nortriptyline rely on the
peripheral noradrenergic system (whereby the
sympathetic fibers sprouting in the dorsal root
ganglia that accompany the nerve injury are the
source of noradrenaline) [8].
The most effective antidepressants for neu-
ropathic pain appear to be TCAs, in particular
desipramine, amitriptyline and its metabolite,
nortriptyline, and imipramine. TCAs are rela-
tively ‘‘dirty drugs’’ that affect multiple targets
and have pleiotropic effects. This lack of selec-
tivity contributes to their efficacy. For instance,
it has been shown that amitriptyline can act as a
local anesthetic by blocking voltage-gated
sodium channels [9]. Antidepressants may have
additional mechanisms of action by modulating
the immune system, which is heavily involved
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in neuropathic pain. Moreover, TCAs may
directly interfere with central sensitization by
blocking NMDA receptors in the spinal cord (see
Kremer et al. [10] for a review on the pharma-
codynamics of antidepressants). TCAs have
been proven to be efficacious in several neuro-
pathic conditions, including painful polyneu-
ropathy, post-herpetic neuralgia, peripheral
nerve injury, and painful diabetic neuropathy
[5].
On the other hand, the multiple actions of
TCAs are also responsible for many adverse drug
reactions that limit their use. In particular,
anticholinergic effects are a major concern
because of the risk of cardiotoxicity, limiting
the dosage to less than 100 mg/day; they also
include dry mouth, orthostatic hypotension,
constipation, and urinary retention. In order to
overcome these problems, selective SNRIs, in
particular duloxetine, have been introduced in
the treatment of neuropathic pain. SNRIs have
been proven to be efficacious in several neuro-
pathic conditions including painful polyneu-
ropathy, post-herpetic neuralgia, painful diabetic
neuropathy, and low back pain [5].
Duloxetine has shown consistent efficacy in
painful diabetic neuropathy and low back pain
[11, 12]. Dosing of duloxetine is simple with
60 mg once or twice daily appearing to be
equally effective. Nausea is the most common
adverse effect of duloxetine, which appears to
be reduced by lowering the dosage to 30 mg
once daily for 1 week before increasing to 60 mg
once daily.
Anticonvulsants Acting at Voltage-Gated
Calcium Channels
Pregabalin and gabapentin are both derived
from GABA, but they have no effect on the
GABAergic system. Their mechanism of action
includes binding to the alpha-2/delta-1 subunit
of the voltage-gated calcium channels in several
areas of the central nervous system (CNS) and
spinal cord in which these channels are
expressed, and this is sufficient to explain their
analgesic, anxiolytic, and anticonvulsant phar-
macological properties [13]. Voltage-gated cal-
cium channels are localized on presynaptic
terminals, where they control neurotransmitter
release. Being voltage-sensitive, they open in
response to action potentials arising from the
periphery and allow the influx of calcium ions,
which is essential for the fusion of synaptic
vesicles and release of neurotransmitters into
the synaptic cleft (Fig. 1). This is the general
mechanism by which these channels are
involved in neurotransmitter release in the
spinal cord and in various areas of the CNS.
Fig. 1 Spinal synapse between the nociceptor and the
spinothalamic neuron Reproduced with permission from [30]
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Voltage-gated calcium channels are comprised
of different subunits: the alpha subunit is
responsible for the formation of the pore
through which calcium ions enter into the cell,
whereas the alpha-2/delta-1, beta, and gamma
are accessory subunits. The alpha-2/delta-1
subunit is responsible for the trafficking, local-
ization, and stabilization of the channel in the
plasma membrane. Interestingly, it has been
demonstrated that the alpha-2/delta-1 subunit
binds at one site to the alpha-1 subunit and at
another site to thrombospondin, a protein of
the extracellular matrix which is produced by
activated astrocytes. Since in experimental
models of neuropathic pain thrombospondin
appears to be upregulated, it is possible to
speculate that the activation of astrocytes in the
spinal cord as a consequence of nerve injury
and the abnormal secretion of thrombospondin
promote the stabilization of voltage-gated cal-
cium channels at the presynaptic terminal
(Fig. 2). Indeed, it has been shown that the
number of voltage-gated calcium channels
increases in neuropathic pain conditions and
may sustain an aberrant neurotransmission in
the spinal cord. Therefore, it is likely that
gabapentinoids, by binding to the alpha-2/
delta-1 subunit, destabilize the macromolecular
complex that keeps the calcium channel on the
surface of the presynaptic terminal, promoting
its internalization [13]. Thus, gabapentinoids
have no direct effect on the currents, but
instead influence the number of available cal-
cium channels in the plasma membrane.
Brainstem structures, from which descend-
ing modulatory fibers originate, may be a key
target of the analgesic action of gabapentinoids,
because alpha-2/delta-1 expression is very high
in these areas. Microinjection of gabapentin
into the locus coeruleus (LC) reduced neuro-
pathic pain behaviors in rats, whilst different
responses in the LC and spinal dorsal horn were
evoked by gabapentin administered intra-
venously in rats with and without L5–L6 spinal
nerve ligation [14]. From this, it was concluded
that gabapentin reduced presynaptic GABA
release in the LC but not in the spinal dorsal
horn. Studies using animal models have sug-
gested that presynaptic release of GABA in the
LC is reduced by alpha-2/delta-1 ligands and
that this restores descending noradrenergic
inhibition after nerve injury [15]. Therefore, the
antinociceptive activities of pregabalin and
gabapentin are also associated with descending
noradrenergic and serotonergic activity, through
which pain transmission in the spinal cord is
modulated. Although the general mechanisms
of action of pregabalin and gabapentin are
similar, important differences exist in terms of
pharmacodynamics [16]. Pregabalin has greater
binding affinity for the alpha-2/delta-1 subunit,
and therefore its analgesic potency in neuro-
pathic pain is higher compared with gaba-
pentin, thus justifying the utility of converting
from gabapentin to pregabalin if the first drug is
not effective enough. Major differences also
exist in terms of pharmacokinetics, especially
absorption. The system-L protein family [L-type
amino acid transporters (LAT)] enables the
transport of large neutral amino acids, includ-
ing phenylalanine, leucine, isoleucine, and
valine; intestinal absorption of gabapentin and
pregabalin is also facilitated by this protein
family. Results from preclinical studies suggest
that gabapentin is transported exclusively by
the LAT1 transporter. This results in dose-lim-
ited absorption, which may be due to saturation
of the facilitated transport process. An addi-
tional pathway also appears to mediate the
absorption of pregabalin, resulting in a high
level of absorption into the bloodstream
[16]. This obviously reflects on bioavailability,
Fig. 2 Mechanism of action of pregabalin and gabapentin
Reproduced with permission from [13]
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which for gabapentin decreases at higher
dosage.
Other pharmacokinetic parameters are simi-
lar for the two drugs and deserve to be discussed
because of their impact in clinical practice. Both
drugs do not undergo metabolism by phase I or
phase II enzymes and are excreted unmodified
by the kidneys. This implies that the two drugs
are not prone to pharmacokinetic drug–drug
interactions and, specifically, are not substrates
of the cytochrome P450 (CYP) system, which is
involved in the metabolism of many other
drugs. This is of significant clinical value,
because the two drugs can be safely used in
comorbid patients on pharmacological poly-
therapy. For the same reason gabapentin and
pregabalin can be safely used in combination
with other analgesic drugs used in the treat-
ment of neuropathic pain. Gabapentinoids have
been proven to be efficacious in several neuro-
pathic conditions such as post-herpetic neural-
gia, painful diabetic neuropathy, painful
polyneuropathy, and low back pain.
In general, pregabalin and gabapentin are
well tolerated. The most commonly reported
adverse effect of pregabalin is dizziness, fol-
lowed by somnolence, dry mouth, edema, and
blurred vision, with treatment discontinuation
due to somnolence occurring in 4% of patients.
For gabapentin, dizziness and somnolence
occur in more than 20% of patients and are the
most commonly reported adverse effects; other
adverse effects include confusion and peripheral
edema. For both drugs, adverse effects are
dose-dependent and reversible [16].
SECOND- AND THIRD-LINE DRUGS
FOR NEUROPATHIC PAIN
Topical Lidocaine
Lidocaine, in the form of 5% patches, was effi-
cacious and had an excellent tolerability profile
in randomized controlled trials of patients with
post-herpetic neuralgia and allodynia, as well as
in patients with allodynia due to neuropathic
pain [17]. Lidocaine blocks voltage-gated sodium
channels that are expressed by nerve fibers,
which are responsible for the propagation of
action potentials. The number, localization,
subtype expression, and activity of these chan-
nels are altered in different forms of neuropathic
pain [18]. Because topical lidocaine can pene-
trate no deeper than 8–10 mm, it is therefore
indicated in well-localized neuropathic pain. Its
efficacy has been documented in different types
of localized neuropathic pain, including
post-herpetic neuralgia, painful diabetic neu-
ropathy, post-surgical and post-traumatic pain
related to incision of the skin [19]. The most
common adverse effects of lidocaine are mild
local reactions due to its topical application.
Lidocaine’s lack of systemic absorption and of
drug interactions can be particularly beneficial in
older patients [19].
Opioids
Strong opioids, such as morphine, oxycodone,
and hydromorphone, and weak opioids, such as
tramadol, are efficacious when compared with
other drugs used for neuropathic pain and are
similar to antidepressants in terms of the
numbers needed to treat [5]. Nevertheless, they
have always been considered second-line drugs
[1], and more recently third-line drugs [5], due
to adverse drug reactions and concerns about
abuse, diversion, and addiction. Tapentadol
represents a new class of dual opioid analgesics,
combining a less potent agonistic activity at
mu-opioid receptors with inhibition of nora-
drenaline uptake, and exploiting the synergy
between the two mechanisms. The innovative
pharmacodynamics and a favorable pharma-
cokinetic profile make tapentadol a unique
opioid analgesic. However, the paucity of
available studies prevented tapentadol from
being included in the most recent systematic
review and meta-analysis on neuropathic pain
[20–22]. For this reason it will not be further
discussed in this review.
The analgesic effect of opioids is due to their
action in the brain, brainstem, spinal cord, and,
under certain circumstances, on peripheral
terminals of primary afferent neurons. All
endogenous opioid peptides, including b-en-
dorphin, enkephalins, and dynorphins, bind
to seven transmembrane G protein-coupled
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receptors, which are divided into three classes:
mu, delta, and kappa receptors. Opioid recep-
tors are coupled to inhibitor G proteins, with
receptor activation inhibiting the adenylate
cyclase as well as the intracellular production of
cAMP. However, the coupling of opioid recep-
tors to calcium and potassium channels is
thought to be a central mechanism of analgesia
production by both endogenous and exogenous
opioids.
In the dorsal horn of the spinal cord, mu
receptors make up the majority of opioid recep-
tors with over 70% of the presynaptic location
occurring at the central terminals of nociceptors
(C and A delta fibers). Opioid receptors located
postsynaptically on dendrites of second-order
spinothalamic neurons and on interneu-
rons make up the remaining 30%. Interneurons
are predominately responsible for the release
of endogenous opioids beta-enkephalin and
endorphins, which act on mu receptors in the
dorsal horn of the spinal cord. The activation of
interneurons is dependent on the activity of
descending pathways or, in a direct manner, by
descending fibers. Inhibition of calcium ion
channels is caused by the activation of presy-
naptic mu receptors, thus preventing neuro-
transmitter release. Activation of potassium ion
channels is caused by the activation of postsy-
naptic mu receptors resulting in the efflux of
potassium ions and hyperpolarization of the
projecting cell. Therefore, stimulation of
mu-opioid receptors in the spinal cord is an
effective mechanism of blocking synaptic trans-
mission, which restricts the number of nocicep-
tive stimuli reaching the thalamus and cortex, in
which a conscious perceptionof pain occurs [23].
In spite of their efficacy, the role of opioids
in the long-term treatment of nonmalignant
pain is controversial for a number of reasons,
including concerns over tolerability, possible
development of tolerance to the analgesic
effect, and the risk of addiction [24]. A system-
atic review of randomized controlled trials of
oral opioids for chronic nonmalignant pain
indicated that approximately 50% of patients
experienced an adverse event with opioids and
more than 20% discontinued treatment because
of adverse events [25]. A more recent Cochrane
review of long-term opioid management of
chronic non-cancer pain reported a rate of dis-
continuation due to adverse events of 22.9% for
oral opioids and 12.1% for transdermal opioids
[26]. There was a significant difference in dis-
continuation rates for orally administered weak
(11.4%) compared with strong (34.1%) opioids.
However, many studies in this Cochrane review
specified that most adverse events were minor
and some of them diminished over time [26].
The most frequent adverse drug reactions to
opioid therapy are nausea and vomiting (tend
to diminish with increasing tolerance), consti-
pation (remains a constant problem), pruritus,
respiratory depression (very uncommon), dry
mouth, urinary retention, drowsiness, and cog-
nitive impairment. Drowsiness and cognitive
impairment should be considered, along with
constipation, the most serious adverse drug
reactions to opioids, because they can seriously
affect the patients’ quality of life. Over the last
few years, addiction, diversion, and abuse have
become the subject of a worldwide debate that
started in the USA in response to the persistent
increase of deaths due to unintentional over-
dose. A detailed discussion of this issue is
beyond the scope of this review. Although the
risk of addiction is inherent to opioids, its rele-
vance in patients suffering from chronic pain,
who take these drugs for pain relief, remains to
be elucidated. It is likely that people with a
previous experience of drug abuse or people
with psychiatric diseases, such as depression or
schizophrenia, are at higher risk of developing
addiction after taking opioids. In other patients
who take opioids for pain relief, the risk is
probably very close to that in the general pop-
ulation [27]. Nevertheless, the use of appropri-
ate tools to identify at-risk patients prior to
initiating treatment with opioids, constant
vigilance on the behavior associated with opi-
oid assumption, and frequent re-evaluation of
the balance between risks and benefits of
long-term opioid therapies should become a
normal attitude among physicians [27].
Other Drugs
A number of additional drugs have shown effi-
cacy in the treatment of neuropathic pain;
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however, these were either single randomized
controlled trials or their efficacy was inconsis-
tent across multiple randomized controlled tri-
als. These drugs represent the third or even
fourth line of treatment options for neuropathic
pain and include specific antidepressants (e.g.,
bupropion) and antiepileptic drugs (carba-
mazepine, lamotrigine), and topical low-con-
centration capsaicin. In general, these drugs
should be reserved for patients who are unable
to tolerate or who fail to respond to first- and
second-line medications.
CONCLUSION
The pharmacotherapy of neuropathic pain is
challenging and for many patients effective
treatment is lacking. There are several reasons
for this, including insufficient knowledge on
efficacious drugs and their appropriate use in
clinical practice. Neuropathic pain is also asso-
ciated with interference with sleep, depression,
and anxiety that, if not properly treated, will
negatively influence the responses to analgesic
drugs. Therefore, evidence-based recommenda-
tions for the pharmacotherapy of neuropathic
pain are essential. However, when choosing a
drug, physicians should also take into consid-
eration comorbidity, prioritizing the use of
those drugs that can satisfy more than one
medical need, as for instance gabapentinoids in
the case of interference of pain with sleep, or
SNRI in the case of associated depression. On
the other hand, comorbidities are also a practi-
cal problem, because patients taking many
medicines are at higher risk of drug–drug
interactions that may be responsible for adverse
drug reactions or therapeutic failure. Since a
large number of drug–drug interactions involve
metabolism by the CYP enzymes, drugs which
do not undergo metabolism by CYP or do not
undergo liver metabolism at all, as in the case of
gabapentinoids, are preferable to other drugs.
This holds true in the case of combination
pharmacotherapy, in which two or more anal-
gesic drugs are co-administered when one is not
enough, a therapeutic strategy that seems to
have evident advantages [28, 29].
Although new innovative molecules are
needed for the successful cure of neuropathic
pain, a deeper understanding of the mechanism
of action of currently available drugs is an
essential step towards an effective clinical
approach that tailors therapies both to the
specific neuropathic disease and to the needs of
an individual patient.
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